Skip to content

Drug Targets and Molecular Basis of Drug Action

CSIR NET medicinal chemistry: enzymes, receptors, ion channels and DNA as drug targets, reversible and irreversible inhibition, agonists, Ki and IC50.

  • 16 min read
  • Updated
On this page · 15 sections
  1. Prerequisites
  2. The Hook: Why a Molecule of 350 Daltons Can Stop a Cell
  3. The Four Classical Target Families
  4. Binding: the Numbers You Must Be Able to Convert
  5. Enzyme Inhibitors: a Chemist’s Classification
  6. Receptors: Agonists, Antagonists and the Numbers
  7. Nucleic Acids as Targets
  8. Selectivity: the Only Thing That Makes a Drug Usable
  9. Memory Tricks
  10. Don’t Confuse
  11. Common Mistakes
  12. Practice
  13. Quick Revision Table
  14. Key Takeaways
  15. What’s Next

Prerequisites

The Hook: Why a Molecule of 350 Daltons Can Stop a Cell

The Four Classical Target Families

TargetWhat the drug doesRepresentative classes
Enzymesblocks catalysis (reversibly or covalently)statins (HMG-CoA reductase), ACE inhibitors, sulfonamides, methotrexate, aspirin
Receptorsmimics or blocks the natural messengerβ-blockers, opioid analgesics, H\(_2\) antagonists, adrenergic agonists
Ion channels and transportersblocks or modulates ion flux / uptakelocal anaesthetics (Na\(^+\) channels), dihydropyridine Ca\(^{2+}\)-channel blockers, proton-pump inhibitors
Nucleic acidsalkylates, intercalates, cross-links or terminates chainsnitrogen mustards, cisplatin, anthracyclines, nucleoside analogues

A fifth, structural, category matters in cancer and antiparasitic chemotherapy: tubulin, where one set of agents (vinca alkaloids, colchicine) blocks polymerisation and another (taxanes) stabilises the microtubule. Both stop mitosis, by opposite chemistry.

graph TD
    A["Drug molecule"] --> B["Binds a macromolecule
(non-covalent complementarity)"] B --> C["Enzyme: inhibition"] B --> D["Receptor: agonism / antagonism"] B --> E["Channel or transporter: block"] B --> F["DNA / RNA: alkylation,
intercalation, chain termination"] C --> G["Biological response
graded by occupancy"] D --> G E --> G F --> G

Binding: the Numbers You Must Be Able to Convert

For a reversible complex \( \mathrm{D} + \mathrm{R} \rightleftharpoons \mathrm{DR} \),

$$K_d = \frac{[\mathrm{D}][\mathrm{R}]}{[\mathrm{DR}]}, \qquad \text{fractional occupancy } \theta = \frac{[\mathrm{D}]}{K_d + [\mathrm{D}]}$$

so \( K_d \) is the free concentration giving half occupancy, and

$$\Delta G^\circ = -RT\ln K_a = +RT\ln K_d$$

Potency scales. p\(K_i\) = −log\(K_i\), pIC\(_{50}\) = −log IC\(_{50}\) (concentrations in mol L⁻¹). IC\(_{50}\) = 10 nM is pIC\(_{50}\) = 8.

IC50 is not Ki

IC\(_{50}\) is an assay number: it depends on how much substrate or radioligand is present. The Cheng–Prusoff relations convert it to a constant of the inhibitor:

$$\text{competitive enzyme inhibition:}\quad K_i = \frac{\mathrm{IC}_{50}}{1 + [\mathrm{S}]/K_M}; \qquad \text{radioligand displacement:}\quad K_i = \frac{\mathrm{IC}_{50}}{1 + [\mathrm{L}]/K_d}$$

Run the assay at \( [\mathrm{S}] = K_M \) and IC\(_{50}\) is exactly \( 2K_i \). For an uncompetitive inhibitor the dependence runs the other way, and for a non-competitive inhibitor with \( \alpha = \alpha' \), IC\(_{50}\) = \( K_i \) at every \( [\mathrm{S}] \) — which is itself a diagnostic.

Enzyme Inhibitors: a Chemist’s Classification

Reversible

ClassBindingKinetic signature (Lineweaver–Burk)Example
Competitiveat the substrate sitelines meet on the \( 1/v \) axis; \( K_M \) apparent risesmethotrexate vs dihydrofolate (DHFR); sulfonamides vs PABA
Uncompetitiveto ES onlyparallel lineslithium on inositol monophosphatase (classical teaching example)
Non-competitive / mixedto a second (allosteric) sitemeet on the \( 1/[\mathrm{S}] \) axis, or off-axismany allosteric modulators

Transition-state analogues are the most potent reversible inhibitors, because an enzyme is by definition complementary to the transition state rather than to the substrate. Statins carry a dihydroxy-acid (or its lactone) that mimics the mevaldyl-type intermediate of HMG-CoA reductase; HIV protease inhibitors replace the scissile amide by a hydroxyethylene or hydroxyethylamine isostere, a non-hydrolysable stand-in for the tetrahedral intermediate; the transition-state idea also explains why phosphonates and boronic acids inhibit hydrolases so strongly.

Irreversible (covalent)

ModeChemistryExample
Affinity label / group-specifican electrophile reacts with an active-site nucleophile after bindingaspirin acetylates a serine of cyclo-oxygenase
Strained-ring acylationthe ring opens on attack by the active-site nucleophileβ-lactams acylate the serine of the transpeptidase (PBP)
Mechanism-based (“suicide”)the enzyme itself converts a latent group into the reactive species5-fluorouracil (as FdUMP) traps thymidylate synthase; allopurinol is oxidised by xanthine oxidase to oxypurinol, which stays bound
Acid-activated prodrugchemistry generated at the site of actionomeprazole cyclises in acid to a sulfenamide that forms a disulfide with a cysteine of the gastric H\(^+\)/K\(^+\)-ATPase

Kinetically, a covalent inhibitor shows time-dependent loss of activity, the apparent first-order rate constant saturating with inhibitor concentration (\( k_{\text{obs}} = k_{\text{inact}}[\mathrm{I}]/(K_I + [\mathrm{I}]) \)), and activity is not restored by dialysis. A merely tight-binding reversible inhibitor regains activity on dilution.

Receptors: Agonists, Antagonists and the Numbers

A receptor transduces binding into a cellular signal. The main families examined are G-protein-coupled receptors (seven transmembrane helices; adrenergic, muscarinic, opioid, histamine), ligand-gated ion channels (nicotinic acetylcholine, GABA\(_A\)), kinase-linked receptors and nuclear (steroid) receptors.

TermMeaning
Affinityhow tightly it binds (\( K_d \), \( K_i \))
Efficacywhat the bound state does (0 for an antagonist, maximal for a full agonist)
Full agonistproduces the maximum tissue response
Partial agonistbinds well but gives a submaximal plateau; in the presence of a full agonist it behaves as an antagonist
Inverse agonistreduces activity below the constitutive baseline
Competitive antagonistshifts the agonist curve right in parallel, \( E_{\max} \) unchanged
Non-competitive / irreversible antagonistdepresses \( E_{\max} \)

EC\(_{50}\) is the concentration giving half the maximal response; it equals \( K_d \) only when occupancy and response are proportional. Tissues with “spare receptors” give EC\(_{50} \ll K_d \).

Schild analysis

For a competitive antagonist B, the dose ratio \( r \) (the factor by which the agonist concentration must be raised to restore the original response) obeys

$$r - 1 = \frac{[\mathrm{B}]}{K_B}, \qquad \log(r - 1) = \log[\mathrm{B}] - \log K_B$$

A plot of \( \log(r-1) \) against \( \log[\mathrm{B}] \) is linear with slope 1 for simple competitive antagonism, and its intercept on the \( \log[\mathrm{B}] \) axis is \( \log K_B \); p\(A_2\) = \( -\log K_B \). A slope differing from unity signals something other than simple competition.

Nucleic Acids as Targets

ModeChemistryExamples
Alkylationaziridinium or similar electrophile attacks N7 of guanine; bifunctional agents cross-link the two strandsnitrogen mustards, nitrosoureas, busulfan
Coordination cross-linksquare-planar Pt(II) binds two adjacent N7 guaninescisplatin and its analogues (see Metal Complexes in Medicine)
Intercalationa flat polycyclic aromatic slots between base pairs, unwinding the helix; often with topoisomerase poisoninganthracyclines, acridines
Groove bindingcrescent-shaped molecules read the minor groovenetropsin-type oligoamides
Chain terminationa nucleoside analogue lacking a 3′-OH (or with it blocked) is incorporated and stops extensionzidovudine (3′-azido), acyclovir (acyclic, no 3′-OH)
Enzyme of nucleic-acid metabolismthe target is an enzyme, with DNA damage downstreamquinolones (DNA gyrase/topoisomerase IV), rifamycins (bacterial RNA polymerase)

Nucleoside antivirals illustrate selectivity beautifully: acyclovir is phosphorylated to the monophosphate essentially only by the virus-encoded thymidine kinase, host kinases complete the triphosphate, and the viral DNA polymerase then incorporates it. A drug that is inert until a viral enzyme activates it is intrinsically selective.

Selectivity: the Only Thing That Makes a Drug Usable

Selective toxicity (Ehrlich’s idea of a “magic bullet”) is achieved by:

  1. A target the host does not have — bacterial cell-wall transpeptidase (β-lactams), bacterial 70S ribosome (tetracyclines, macrolides, aminoglycosides), viral reverse transcriptase or protease.
  2. A target the host has in a different form — bacterial dihydrofolate reductase binds trimethoprim far more tightly than the human enzyme does; the human pathway also differs in that we take up folate rather than synthesise it, which is why sulfonamides (dihydropteroate synthase inhibitors) are selective at all.
  3. Differential uptake or activation — prodrugs activated by a pathogen or tumour enzyme.
  4. Subtype selectivity — β\(_1\)- versus β\(_2\)-adrenoceptors, COX-1 versus COX-2, kinase selectivity profiles.

The therapeutic index, TD\(_{50}\)/ED\(_{50}\) (or LD\(_{50}\)/ED\(_{50}\) in animals), quantifies the margin between effect and harm; it is large for penicillins and small for cytotoxic anticancer drugs, which is exactly why one is given casually and the other is not.

Memory Tricks

Don’t Confuse

ThisvsThat
\( K_i \) (constant of the inhibitor)IC\(_{50}\) (depends on \( [\mathrm{S}] \) or \( [\mathrm{L}] \) in the assay)
\( K_d \) (binding)EC\(_{50}\) (response); equal only without receptor reserve or signal amplification
AffinityEfficacy — an antagonist can have very high affinity and zero efficacy
Competitive antagonist (parallel right shift, \( E_{\max} \) kept)Irreversible antagonist (\( E_{\max} \) depressed)
Transition-state analogue (reversible, very tight)Suicide substrate (covalent, time-dependent)
Antimetabolite (resembles a metabolite, blocks its pathway)Antagonist (blocks a receptor)
Potency (concentration needed)Efficacy (height of the plateau)
Therapeutic index TD\(_{50}\)/ED\(_{50}\)Selectivity ratio between two targets

Common Mistakes

Practice

All questions below are original practice questions written for this page. They are not from any CSIR NET paper.

Level 1: Foundation

  1. Write the Cheng–Prusoff relation for a competitive enzyme inhibitor.
  2. What does a Schild plot of slope 1 indicate?
  3. Name the kinetic observation that distinguishes a mechanism-based inhibitor from a competitive one.
Answers
  1. \( K_i = \mathrm{IC}_{50}/(1 + [\mathrm{S}]/K_M) \).
  2. Simple competitive antagonism; the \( \log[\mathrm{B}] \) intercept gives \( \log K_B \).
  3. Time-dependent, saturable loss of activity that is not reversed by dialysis or dilution.

Level 2: Part B Style

Practice Q1. An inhibitor gives IC\(_{50}\) = 90 nM in an assay run at \( [\mathrm{S}] = 2K_M \). If the inhibition is competitive, \( K_i \) is:

(a) 30 nM (b) 45 nM (c) 90 nM (d) 270 nM

Answer: (a) 30 nM

\( K_i = 90/(1 + 2) = 30 \) nM. Option (b) uses \( 1 + [\mathrm{S}]/K_M = 2 \) (i.e. \( [\mathrm{S}] = K_M \)); option (d) multiplies instead of dividing.

Practice Q2. A compound binds its receptor with \( K_d = 1.0 \times 10^{-8} \) mol L⁻¹ at 298 K. The standard free energy of binding is closest to:

(a) −27 kJ mol⁻¹ (b) −46 kJ mol⁻¹ (c) −57 kJ mol⁻¹ (d) +46 kJ mol⁻¹

Answer: (b) −46 kJ mol⁻¹

\( \Delta G^\circ = RT\ln K_d = 8.314 \times 298.15 \times \ln(10^{-8}) = -45.7 \) kJ mol⁻¹. Option (c) corresponds to \( K_d = 10^{-10} \); option (d) has the sign of \( \ln K_a \) reversed.

Practice Q3. Which pairing is incorrect?

(a) Sulfonamide — dihydropteroate synthase (b) Methotrexate — dihydrofolate reductase (c) β-Lactam — bacterial transpeptidase (d) Acyclovir — bacterial 30S ribosomal subunit

Answer: (d)

Acyclovir is a guanosine analogue activated by viral thymidine kinase and acting as a DNA chain terminator at the viral DNA polymerase. The 30S subunit is the target of aminoglycosides and tetracyclines.

Practice Q4. In the presence of a fixed concentration of an antagonist, the agonist dose–response curve is shifted to the right in parallel with no change in maximum response. The antagonist is:

(a) competitive and reversible (b) irreversible (c) an inverse agonist (d) a partial agonist

Answer: (a)

Parallel right shift with \( E_{\max} \) preserved is the signature of surmountable, competitive antagonism. An irreversible antagonist depresses \( E_{\max} \); a partial agonist caps the plateau below the full agonist maximum.

Level 3: Part C Style

Practice Q5. An inhibitor of a serine hydrolase shows: (i) no inhibition when added at the moment of assay, but near-complete inhibition after 20 min pre-incubation; (ii) \( k_{\text{obs}} \) that rises with \( [\mathrm{I}] \) and saturates; (iii) no recovery of activity after exhaustive dialysis; (iv) complete protection by saturating substrate during pre-incubation. Which statements are correct?

  1. The inhibitor forms a covalent adduct.
  2. Binding occurs at the active site before the covalent step.
  3. The data are consistent with a reversible competitive inhibitor of very low \( K_i \).
  4. Saturation of \( k_{\text{obs}} \) implies a non-covalent complex precedes inactivation.

(a) 1, 2 and 4 only (b) 1 and 3 only (c) 2, 3 and 4 only (d) 1, 2, 3 and 4

Answer: (a) 1, 2 and 4 only
  1. Time dependence plus failure to recover on dialysis. Correct.
  2. Substrate protection localises the event to the active site. Correct.
  3. A reversible inhibitor, however tight, recovers on dialysis and inhibits immediately. Wrong.
  4. Saturation kinetics (\( k_{\text{obs}} = k_{\text{inact}}[\mathrm{I}]/(K_I + [\mathrm{I}]) \)) require a pre-formed EI complex. Correct.

Practice Q6. A competitive antagonist is tested at three concentrations; the agonist dose ratios \( r \) are:

\( [\mathrm{B}] \) / mol L⁻¹\( 1.0\times10^{-8} \)\( 1.0\times10^{-7} \)\( 1.0\times10^{-6} \)
\( r \)2.011101

Which statements are correct?

  1. The Schild plot has unit slope.
  2. \( K_B = 1.0 \times 10^{-8} \) mol L⁻¹.
  3. p\(A_2\) = 8.
  4. At \( [\mathrm{B}] = 1.0 \times 10^{-5} \) mol L⁻¹ the predicted dose ratio is about 1001.

(a) 1 and 2 only (b) 1, 2, 3 and 4 (c) 2, 3 and 4 only (d) 1 and 4 only

Answer: (b) 1, 2, 3 and 4

\( r - 1 \) = 1.0, 10, 100 — exactly proportional to \( [\mathrm{B}] \), so the plot of \( \log(r-1) \) against \( \log[\mathrm{B}] \) has slope 1. \( K_B = [\mathrm{B}]/(r-1) = 10^{-8} \) at every point, so p\(A_2\) = 8 (the concentration giving \( r = 2 \) is indeed \( 10^{-8} \)). Extrapolating, \( r - 1 = 10^{-5}/10^{-8} = 1000 \). All four correct.

Practice Q7. Two inhibitors of the same enzyme are compared at 298 K: A has \( K_i = 1.0 \) µM, B has \( K_i = 1.0 \) nM. Which statements are correct?

  1. B binds about 17 kJ mol⁻¹ more tightly than A.
  2. The difference corresponds to three orders of magnitude in \( K_i \).
  3. If B is a transition-state analogue and A a substrate analogue, the result is expected.
  4. B must act covalently.

(a) 1, 2 and 3 only (b) 2 and 4 only (c) 1, 2, 3 and 4 (d) 3 and 4 only

Answer: (a) 1, 2 and 3 only
  1. \( \Delta\Delta G = RT\ln(10^3) = 3 \times 5.71 = 17.1 \) kJ mol⁻¹. Correct.
  2. From µM to nM is \( 10^3 \). Correct.
  3. Enzymes are complementary to the transition state, so its analogues bind far more tightly than substrate analogues. Correct.
  4. Nanomolar affinity says nothing about covalency. Wrong.

Quick Revision Table

IdeaFormula / fact
Occupancy\( \theta = [\mathrm{D}]/(K_d + [\mathrm{D}]) \)
Free energy\( \Delta G^\circ = RT\ln K_d \); one log unit = 5.7 kJ mol⁻¹ (298 K)
Cheng–Prusoff (enzyme)\( K_i = \mathrm{IC}_{50}/(1 + [\mathrm{S}]/K_M) \)
Cheng–Prusoff (radioligand)\( K_i = \mathrm{IC}_{50}/(1 + [\mathrm{L}]/K_d) \)
Schild\( r - 1 = [\mathrm{B}]/K_B \); slope 1; p\(A_2 = -\log K_B \)
Covalent inhibition\( k_{\text{obs}} = k_{\text{inact}}[\mathrm{I}]/(K_I + [\mathrm{I}]) \); time-dependent, non-dialysable
Transition-state analoguetightest reversible binders; HIV protease hydroxyethylene isostere
Suicide substrateactivated by the target enzyme (5-FU → FdUMP; allopurinol → oxypurinol)
Chain terminatorsno free 3′-OH: zidovudine, acyclovir
Selectivityabsent target, different target, different activation, different subtype
Therapeutic indexTD\(_{50}\)/ED\(_{50}\)

Key Takeaways

What’s Next